Genentech, Inc.

The Walter and Eliza Hall Institute of Medical Research

Abbvie Inc.

Abbott Laboratories Corporation

The Walter and Eliza Hall Medical Research Institute

Peter Edward Czabotar

Andrew J Souers

Steven Elmore

Guillaume Laurent Lessene

Peter Colman

Keith G Watson

John A Flygare

Chudi Obioma Ndubaku

Jonathan Bayldon Baell

Wayne J Fairbrother

Andrew M Petros

Danette Dudley

Brad E Sleebs

Chinh Thien Bui

Brian John Smith

George Nikolakopoulos

Carl Steven Rye

Le Wang

Zhi-Fu Tao

Steven W Elmore

Keith Geoffrey Watson

Brad Edmund Sleebs

Danette A Dudley

George A Doherty

Xilu Wang

Michael D Wendt

Milan Bruncko

Aaron R Kunzer

Gary T Wang

Gerard M Sullivan

Hong Ding

Xiaohong Song

Lisa A Hasvold

William J McClellan

Robert A Mantei

Cheol-Min Park

Laura A Hexamer

Yujia Dai

Chang H Park

Kurt Deshayes

Xiahong Song

Peter Malcom Colman

In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Compounds and methods of use

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

In one aspect, the present invention provides for a compound of Formula I in which the variable X, X, X, X, Q, A, R, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Heterocyclic compounds and methods of use

Growing community of inventors

North Melbourne, Australia

Peter Edward Czabotar